First-line therapy for metastatic kidney cancer: Is two better than one?
An educational symposium was held from 8-10 August as part [...]
The impact of COVID-19 pandemic on treatment for metastatic kidney cancer
A recent online survey involving 41 kidney cancer experts worldwide [...]
Impact of COVID-19 on the treatment of metastatic kidney cancer
Because so little was known about coronavirus at the start [...]
Re-treatment with immune checkpoint inhibitors in kidney cancer patients
Immune checkpoint inhibitor combinations for the treatment of patients with [...]
New targeted therapy shows potential for previously treated metastatic kidney cancer
A phase II study published in Frontiers in Oncology last [...]
ASCO 2020: Implications of the research presented at ASCO 2020 on the treatment of advanced kidney cancer
In this video presentation, Dr Toni Chouieri discusses the SAVOIR, [...]
Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients
A study published in Clinical Genitourinary Cancer this month looks [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
Cabozantinib in combination with immunotherapy for advanced kidney cancer
In this video interview, Dr Monty Pal from the City [...]
ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer
A retrospective analysis of data from the International Metastatic Renal [...]
